Chemotherapy: Dose-dense treatment for triple-negative breast cancer

Nature Reviews Clinical Oncology

Volumn 7, Issue 2, 2010, Pages 79-80

  Amir, Eitan ^a   Ocana, Alberto ^a   Freedman, Orit ^a   Clemons, Mark ^b   Seruga, Bostjan ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE SEQUENCE; GENE OVEREXPRESSION; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY; TREATMENT OUTCOME;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; TREATMENT OUTCOME;

EID: 76449115473     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.231     Document Type: Short Survey

References (10)

1. Bonadonna, G. et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N. Engl. J. Med. 294, 405-410 (1976).
2. early Breast Cancer Trialists' Collaborative Group (eBCTCG) effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005).
3. De Laurentiis, M. et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J. Clin. Oncol. 26, 44-53 (2008).
4. Citron, M. L. et al. Randomized trial of dosedense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup Trial C9741/ Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. 21, 1431-1439 (2003).
5. sparano Joseph, A. et al. weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer. N. Engl. J. Med. 358, 1663-1671 (2008).
6. venturini, M. et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J. Natl Cancer Inst. 97, 1724-1733 (2005). (Pubitemid 41782282)
7. Berry, D. A. et al. estrogen-Receptor status and Outcomes of Modern Chemotherapy for Patients with node-Positive Breast Cancer. JAMA 295, 1658-1667 (2006).
8. norton, L. & simon, R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep. 61, 1307-1317 (1977).
9. Del Mastro, L. et al. HeR2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients. Br. J. Cancer 93, 7-14 (2005). (Pubitemid 41076246)
10. Dang, C. et al. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HeR-2/neu overexpressed/amplified breast cancer. J. Clin. Oncol. 26, 1216-1222 (2008